Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.38 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | MAOA | P21397 | 1/20 | 0.38 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.38 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.38 |
| ▸ | HTR2B | P41595 | 1/20 | 0.38 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.35 |
| ▸ | LPL | P06858 | 5/20 | 0.33 |
| ▸ | LIPG | Q9Y5X9 | 5/20 | 0.33 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | ACHE | P22303 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
| ▸ | F11 | P03951 | 1/20 | 0.31 |
| ▸ | ESR1 | P03372 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12205429 | 0.83 | LPL (0.37) | HIF1ALPLLIPGP2RX7MAPK1 | |
| SCHEMBL23174510 | 0.82 | CYP3A4 (0.34) | CYP3A4CHRM1ALOX15MAOATBXA2R | |
| SCHEMBL30077918 | 0.82 | CYP3A4 (0.34) | CYP3A4CHRM1ALOX15MAOATBXA2R | |
| SCHEMBL21831566 | 0.81 | LPL (0.34) | CYP3A4HIF1ALPLLIPGP2RX7 | |
| SCHEMBL24733131 | 0.81 | LPL (0.42) | HIF1ALPLLIPGP2RX7F11 | |
| SCHEMBL25560010 | 0.79 | LPL (0.33) | LPLLIPGP2RX7MAPK1 | |
| SCHEMBL22442104 | 0.79 | LPL (0.44) | LPLLIPGP2RX7MAPK1 | |
| SCHEMBL17838322 | 0.79 | LPL (0.33) | LPLLIPGP2RX7MAPK1 | |
| SCHEMBL22655171 | 0.79 | SELL (0.37) | HIF1ALPLLIPGP2RX7ALDH1A1 | |
| SCHEMBL30412775 | 0.79 | SELL (0.37) | HIF1ALPLLIPGP2RX7ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250115613-A1 | DIARYL COMPOUND AS TUBULIN/SRC DUAL TARGET INHIBITOR | Wuhan Humanwell Innovative Drug Research and Development Center Limited Company (CN) | 2025-04-10 | — | — | US | disclosed |
| EP-4464700-A1 | DIARYL COMPOUND AS TUBULIN/SRC DUAL TARGET INHIBITOR | Wuhan Humanwell Innovative Drug Research and Development Center Limited Company (CN) | 2024-11-20 | — | — | EP | disclosed |
| WO-2023134752-A1 | DIARYL COMPOUND AS TUBULIN/SRC DUAL TARGET INHIBITOR | 武汉人福创新药物研发中心有限公司 | 2023-07-20 | — | — | WO | disclosed |
| CN-116444427-A | Diaryl compounds for tubulin-SRC double-target inhibitor | 武汉人福创新药物研发中心有限公司 | 2023-07-18 | — | — | CN | disclosed |
| WO-2022216945-A1 | MACROCYCLIC MCL1 INHIBITORS AND USES THEREOF | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2022-10-13 | — | — | WO | disclosed |
| WO-2015024448-A1 | BENZO PIPERIDINE RING AND BENZO MORPHOLINE RING COMPOUNDS, MANUFACTURING METHOD THEREFOR, AND MEDICAL APPLICATIONS THEREOF | 上海润诺生物科技有限公司 (CN) | 2015-02-26 | — | — | WO | disclosed |
| US-7138530-B2 | Thiophene amidines, compositions thereof, and methods of treating complement-mediated diseases and conditions | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2006-11-21 | — | — | US | disclosed |
| US-7109354-B2 | Thiophene amidines, compositions thereof, and methods of treating complement-mediated diseases and conditions | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2006-09-19 | — | — | US | disclosed |
| EP-1549632-A4 | NOVEL THIOPHENE AMIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATING COMPLEMENT-MEDIATED DISEASES AND CONDITIONS | DIMENSIONAL PHARM INC (US) | 2005-11-09 | — | — | EP | disclosed |
| US-20050234081-A1 | Novel thiophene amidines, compositions thereof, and methods of treating complement-mediated diseases and conditions | SUBASINGHE NALIN | 2005-10-20 | — | — | US | disclosed |
| EP-1549632-A1 | NOVEL THIOPHENE AMIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATING COMPLEMENT-MEDIATED DISEASES AND CONDITIONS | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2005-07-06 | — | — | EP | disclosed |
| US-20040009995-A1 | Novel thiophene amidines, compositions thereof, and methods of treating complement-mediated diseases and conditions | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2004-01-15 | — | — | US | disclosed |
| WO-2003099805-A1 | NOVEL THIOPHENE AMIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATING COMPLEMENT-MEDIATED DISEASES AND CONDITIONS | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2003-12-04 | — | — | WO | disclosed |
| WO-2003028724-A1 | CHK1 KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2003-04-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050234081-A1 | Novel thiophene amidines, compositions thereof, and methods of treating complement-mediated diseases and conditions | C5, C9, C1R | CYP3A4 1530/4885CHRM1 79/4885ALOX15 348/4885 |
| US-20250115613-A1 | DIARYL COMPOUND AS TUBULIN/SRC DUAL TARGET INHIBITOR | SRC, DSTYK, TUBB1 | CYP3A4 1996/4885CHRM1 3535/4885ALOX15 4672/4885 |
| US-20040009995-A1 | Novel thiophene amidines, compositions thereof, and methods of treating complement-mediated diseases and conditions | C5, C9, C1R | CYP3A4 1112/4885CHRM1 288/4885ALOX15 385/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.